How SRD5A3 and IGF2BP3 Affect Bladder Cancer and Chemotherapy Resistance
Author Information
Author(s): Liao Kai, Li Jing, He Caixian, Peng Jiyong
Primary Institution: Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University
Hypothesis
The study investigates the role of SRD5A3 and IGF2BP3 in bladder cancer and their impact on cisplatin resistance.
Conclusion
The study found that SRD5A3 and IGF2BP3 contribute to bladder cancer progression and cisplatin resistance, suggesting potential therapeutic targets.
Supporting Evidence
- SRD5A3 was found to be upregulated in cisplatin-resistant bladder cancer cells.
- Knockdown of SRD5A3 and IGF2BP3 reduced cell proliferation and chemoresistance.
- Animal studies showed that SRD5A3 knockdown inhibited tumor growth in xenografts.
Takeaway
This study shows that two proteins, SRD5A3 and IGF2BP3, help bladder cancer cells survive chemotherapy, which means targeting them could help treat the cancer better.
Methodology
The study used human bladder cancer tissues, cell lines, and animal models to analyze the roles of SRD5A3 and IGF2BP3 in cisplatin resistance.
Limitations
The exact mechanisms by which SRD5A3 contributes to cisplatin resistance remain unclear.
Participant Demographics
Among the 30 bladder cancer patients, there were 21 males and 9 females, with varying stages of cancer.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website